Evidence map›Paper›PMID 40881870›Full record

ArticleFrontiers in oncology2025

Implementing comprehensive geriatric assessment in an academic hematologic outpatient setting: experiences from medical doctors and patients.

Steven Pierre Hiltgen, Heike A Bischoff-Ferrari, Michael Gagesch, Alexander Kaltenborn, Markus G Manz, Max J Rieger, Rahel Schwotzer, Sebastian M Stolz, Thorsten Zenz, Wiebke Rösler

Abstract read
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Steven Pierre HiltgenDepartment of Medical Oncology and Hematology, University Hospital Zurich, Zurich, Switzerland.
Heike A Bischoff-FerrariCentre on Aging and Mobility, University of Zurich, Zurich, Switzerland.
Michael GageschCentre on Aging and Mobility, University of Zurich, Zurich, Switzerland.
Alexander KaltenbornKAMIQ Institute, Detern, Germany.
Markus G ManzDepartment of Medical Oncology and Hematology, University Hospital Zurich, Zurich, Switzerland.
Max J RiegerDepartment of Medical Oncology and Hematology, University Hospital Zurich, Zurich, Switzerland.
Rahel SchwotzerDepartment of Medical Oncology and Hematology, University Hospital Zurich, Zurich, Switzerland.
Sebastian M StolzDepartment of Medical Oncology and Hematology, University Hospital Zurich, Zurich, Switzerland.
Thorsten ZenzDepartment of Medical Oncology and Hematology, University Hospital Zurich, Zurich, Switzerland.
Wiebke RöslerDepartment of Medical Oncology and Hematology, University Hospital Zurich, Zurich, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The incidence of most cancers increases with age and cancer is a leading cause of morbidity and mortality in the older population. Older cancer patients frequently have additional co-morbidities and functional decline, which can substantially affect treatment outcomes. Major oncology societies recommend a screening for geriatric impairments in patients at risk (e.g. G8), followed by a comprehensive geriatric assessment (CGA). Nevertheless, CGA is often not established in routine care. We describe the implementation process of CGA in patients with hematological cancers at the University Hospital of Zurich. We evaluate its benefits, its perception by physicians and patients, and identify potential obstacles and solutions to allow integration into daily clinical practice. Materials and Methods: This retrospective, single-center observational study was conducted at the University Hospital of Zurich. Patients aged ≥65 years with hematological malignancies who underwent CGA within the last 5 years were included. Patients were referred for CGA based on physicians' choice. All data were extracted from electronic medical records and later analyzed. Perception of the CGA by patients and physicians was assessed by a questionnaire. Results: 46 patients who underwent CGA between April 2019 and July 2023 were included in this study. 89.1% showed at least one impaired domain in the CGA. For 98% of patients, one or more interventions were suggested. Low G8 scores were significantly associated with detected CGA-impairments (p<0.05). 70% of patients found the CGA and its resulting recommendations useful and reported benefiting from the process. 75% of the physicians rated the resulting CGA report as helpful for their clinical assessment. Conclusion: Our data support the use of a CGA in older patients with hematological cancers based on positive feedback on its implementation, from both patients and treating physicians. Our results emphasize the need for a dedicated geriatric assessment in an older cancer population as it contributes to a more comprehensive medical evaluation and potentially improves overall care and quality of life for patients.

Indexed as

geriatric hematologygeriatric managementhematologic malignanciesimplementation of geriatric assessmentpatients’ perspective

Identifiers

PMID40881870
PMCPMC12380937

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.